SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: OldAIMGuy who wrote (52004)12/27/2022 3:06:18 PM
From: Art Bechhoefer1 Recommendation

Recommended By
OldAIMGuy

  Respond to of 52153
 
Gene editing is still too expensive to be widely used. Crispr also doesn't have enough financial strength to avoid either an issue of more stock or a profit-sharing collaboration with larger drug firms. My long term preference is for Intellia, because of its in vivo technology, but at the moment, I don't own either one.

Art